CUREVAC NV (CVAC) Stock Fundamental Analysis
NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
Taking everything into account, CVAC scores 6 out of 10 in our fundamental rating. CVAC was compared to 561 industry peers in the Biotechnology industry. CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CVAC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CVAC had positive earnings in the past year.
CVAC had a positive operating cash flow in the past year.
In the past 5 years CVAC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 20.20%, CVAC belongs to the best of the industry, outperforming 98.04% of the companies in the same industry.
With an excellent Return On Equity value of 23.28%, CVAC belongs to the best of the industry, outperforming 97.50% of the companies in the same industry.
The Return On Invested Capital of CVAC (20.88%) is better than 97.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.2% | ||
| ROE | 23.28% | ||
| ROIC | 20.88% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 30.30%, CVAC belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.
With an excellent Operating Margin value of 33.54%, CVAC belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
CVAC's Gross Margin of 80.23% is amongst the best of the industry. CVAC outperforms 85.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.54% | ||
| PM (TTM) | 30.3% | ||
| GM | 80.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CVAC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CVAC has about the same amount of shares outstanding.
CVAC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CVAC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.93 indicates that CVAC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.93, CVAC belongs to the best of the industry, outperforming 84.31% of the companies in the same industry.
CVAC has a debt to FCF ratio of 0.47. This is a very positive value and a sign of high solvency as it would only need 0.47 years to pay back of all of its debts.
The Debt to FCF ratio of CVAC (0.47) is better than 96.08% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that CVAC is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, CVAC is doing worse than 62.57% of the companies in the same industry.
Although CVAC does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.47 | ||
| Altman-Z | 7.93 |
ROIC/WACC2.96
WACC7.05%
2.3 Liquidity
A Current Ratio of 7.28 indicates that CVAC has no problem at all paying its short term obligations.
CVAC has a better Current ratio (7.28) than 69.34% of its industry peers.
CVAC has a Quick Ratio of 7.27. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CVAC (7.27) is better than 69.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.28 | ||
| Quick Ratio | 7.27 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 166.39%, which is quite impressive.
The Revenue has grown by 895.54% in the past year. This is a very strong growth!
Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)895.54%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
Based on estimates for the next years, CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-172.19%
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
EPS Next 5Y-22.5%
Revenue Next Year-84.72%
Revenue Next 2Y-54.11%
Revenue Next 3Y-32.09%
Revenue Next 5Y-11.14%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CVAC is valuated cheaply with a Price/Earnings ratio of 4.54.
Based on the Price/Earnings ratio, CVAC is valued cheaper than 98.57% of the companies in the same industry.
CVAC is valuated cheaply when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.54 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.29% of the companies are valued more expensively.
98.04% of the companies in the same industry are more expensive than CVAC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.98 | ||
| EV/EBITDA | 1.91 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
CVAC's earnings are expected to decrease with -32.41% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
5. Dividend
5.1 Amount
No dividends for CVAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CVAC (5/23/2025, 9:37:08 AM)
4.18
+0.02 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.11%
Inst Owner Change-0.87%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap941.17M
Analysts78.46
Price Target6.32 (51.2%)
Short Float %5.2%
Short Ratio8.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)98.42%
Min EPS beat(2)35.41%
Max EPS beat(2)161.44%
EPS beat(4)2
Avg EPS beat(4)36.29%
Min EPS beat(4)-33.3%
Max EPS beat(4)161.44%
EPS beat(8)4
Avg EPS beat(8)5.44%
EPS beat(12)6
Avg EPS beat(12)2.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)242.44%
Min Revenue beat(2)118.24%
Max Revenue beat(2)366.65%
Revenue beat(4)4
Avg Revenue beat(4)161.47%
Min Revenue beat(4)0.83%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)63.93%
Revenue beat(12)6
Avg Revenue beat(12)49.89%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.63%
PT rev (3m)-19.63%
EPS NQ rev (1m)-35.71%
EPS NQ rev (3m)29.63%
EPS NY rev (1m)0.64%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)-47.85%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)6.55%
Revenue NY rev (3m)6.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.54 | ||
| Fwd PE | N/A | ||
| P/S | 1.56 | ||
| P/FCF | 9.98 | ||
| P/OCF | 8.17 | ||
| P/B | 1.19 | ||
| P/tB | 1.24 | ||
| EV/EBITDA | 1.91 |
EPS(TTM)0.92
EY22.01%
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)0.42
FCFY10.02%
OCF(TTM)0.51
OCFY12.24%
SpS2.69
BVpS3.5
TBVpS3.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.2% | ||
| ROE | 23.28% | ||
| ROCE | 24.58% | ||
| ROIC | 20.88% | ||
| ROICexc | 62.23% | ||
| ROICexgc | 69.35% | ||
| OM | 33.54% | ||
| PM (TTM) | 30.3% | ||
| GM | 80.23% | ||
| FCFM | 15.58% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.47 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 98.06% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 77.21 | ||
| Cash Conversion | 51.36% | ||
| Profit Quality | 51.43% | ||
| Current Ratio | 7.28 | ||
| Quick Ratio | 7.27 | ||
| Altman-Z | 7.93 |
F-Score7
WACC7.05%
ROIC/WACC2.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-172.19%
EPS Next 2Y-61.36%
EPS Next 3Y-32.41%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)895.54%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.72%
Revenue Next 2Y-54.11%
Revenue Next 3Y-32.09%
Revenue Next 5Y-11.14%
EBIT growth 1Y164.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-154%
EBIT Next 3Y7.36%
EBIT Next 5Y10.78%
FCF growth 1Y125.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y138.02%
OCF growth 3YN/A
OCF growth 5YN/A